Q3 FY26 results: consolidated PAT up 66% YoY, revenue up 49%

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹638.00

prior close

₹659.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+2.6%+0.1% vs market

Specialty Chemicals peers, median of 88sector+1.7%+1.0% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 1.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-0.9

15m

-0.8

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7+2.6+0.1+1.7+1.0

Next day

+3.4+3.6-0.2+2.4+1.1

+3.8+3.1+0.7+2.5+1.2

+5.0+2.6+2.4+1.3+3.7

+5.1+1.1+4.0+0.0+5.1

+3.4+0.3+3.1-1.6+5.1

+6.0+1.6+4.3-0.7+6.6

15d

-6.3-3.9-2.3-6.7+0.4

-12.5-8.1-4.4-8.8-3.7

-3.8-3.1-0.7-4.9+1.1

+1.7+9.2-7.4+5.9-4.1

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 88Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudeep Pharma reported Q3 FY26 standalone revenue of Rs 90.28 crore (up 8% YoY) and PAT of Rs 26.87 crore (up 30% YoY). Consolidated Q3 revenue jumped 49% YoY to Rs 172.34 crore with PAT at Rs 47.70 crore (up 66% YoY), helped by the May 2025 acquisition of NSS Ireland. For 9M FY26, consolidated PAT grew 33% to Rs 125.75 crore on revenue of Rs 459.92 crore. Board appointed Sharp and Tannan Associates as internal auditor for FY27. First results since Nov 2025 IPO listing on NSE and BSE.

Likely market impact

Strong debut results post Nov 2025 IPO. Consolidated PAT up 66% YoY on Ireland acquisition boost. Rs 75.8 crore IPO funds still unutilized.